Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Summary

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.

Timeline

Start

2021-05-07

Primary completion

2023-09

Completion

2023-10

Drugs

Indications